COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.
Academic rigor, journalistic flair
Articles on Drug industry
Displaying all articles
In the 1980s, CSIRO and its university collaborators set into motion a chain of events that would lead to the production of relenza, the first drug to successfully treat the flu.
There’s a big market for new treatments for TB, malaria and other ailments. But most of these diseases afflict low-income people unable to pay for medicine.
Just because they can’t prescribe medications that does not mean nurses have no influence on important decisions for patient care.
Top contributors
-
Professor of Innovation Studies, Swinburne University of Technology
-
Postdoctoral Fellow, University of Sydney
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Professor of Chemistry; Interim Chair of the Chemistry Department, University of South Florida
-
Visiting Fellow, Swinburne University of Technology
-
Associate Professor of Comparative Effectiveness and Outcomes Research, University of Connecticut
